Mila was four when she was first diagnosed with B-cell acute lymphoblastic leukemia. Standard chemotherapy worked — twice — but the leukemia came back twice. Her doctors in Moscow told the family that CAR-T was the best remaining option, but the waiting list at home was long and the price abroad was beyond reach.
The family contacted MedBridge Pediatrics on a Sunday night. By Wednesday, Mila’s records had been reviewed by the pediatric cellular therapy team in Beijing, and a preliminary plan with transparent costs was in the family’s hands — in Russian.
In Beijing, Mila’s T-cells were collected and engineered. Her mother remembers the playroom most: “Mila thought she was going to an art class every morning.” On day 28 after infusion, her bone marrow showed complete remission, MRD-negative.
The team kept her for monitoring through the cytokine-release window, then coordinated a handover plan with her Moscow hematologists. MedBridge arranged bilingual discharge documents and a remote follow-up schedule.
Outcome
MRD-negative complete remission at day 28. Eighteen months later, Mila remains in remission and has started primary school.
“They treated Mila like a child, not a diagnosis. Every nurse knew her favorite color. — Mila’s mother”
All stories are anonymized composites based on real treatment journeys, shared with family consent. Names are pseudonyms and identifying details have been changed.
